{"id":"W3121448666","doi":"10.1200/jco.2021.39.3_suppl.tps152","title":"Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Antibody; Chemotherapy; Bevacizumab; Internal medicine; Oncology; Progressive disease; Cancer; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007227389,0.001074729,0.001011549,0.000314848,0.000310182,0.0008691376,0.0006289645,0.000929257,0.004023424],"category_scores_gemma":[0.0003459852,0.0003725438,0.0008600036,0.0002885217,0.0004989055,0.000631368,0.0003819295,0.001885601,0.0009423175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025462,"about_ca_system_score_gemma":0.001690645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001274764,"about_ca_topic_score_gemma":0.003111787,"domain_scores_codex":[0.9997863,0.00006863963,0.000009523385,0.00004484067,0.00002083637,0.00006978014],"domain_scores_gemma":[0.9996898,0.00002931784,0.00006067461,0.0000168829,0.00001455157,0.0001887657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7819376,0.03861929,0.008051385,0.0006414587,0.001176529,0.0003361405,0.0002282245,0.002435447,0.05733575,0.000566342,0.005827521,0.1028442],"study_design_scores_gemma":[0.4438578,0.5318209,0.01126806,0.00003995061,0.0004499878,0.0002945028,0.0000587641,0.001604242,0.005519577,0.0002582904,0.004798455,0.00002941579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906597,0.001419355,0.0005535297,0.0004758853,0.0001331725,0.002448535,0.001247213,0.0001267656,0.002935819],"genre_scores_gemma":[0.989409,0.0007728445,0.001239858,0.0008546103,0.00009308456,0.002369275,0.00219881,0.00002176708,0.003040878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004023424,"threshold_uncertainty_score":0.01345974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04148958753402491,"score_gpt":0.4308969426276206,"score_spread":0.3894073550935957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}